Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Dana Faratian

Showing results (1-10 of 47) with videos related to

Pageof 5
Sort By:
Breast Cancer Research : BCR|December 22, 2010
Systems pathologyDana Faratian
Current Drug Targets|September 15, 2012
Molecular pathology in therapeutics: where are we now, and where are we going?David J Harrison, Dana Faratian
Onkologie|November 6, 2009
The importance of growth factors and steroid hormones in ovarian cancerSimon P Langdon, Dana Faratian, David J Harrison
Histopathology|March 25, 2009
Rapid screening of tissue microarrays for Her-2 fluorescence in situ hybridization testing is an accurate, efficient and economic method of providing an entirely in situ hybridization-based Her-2 testing serviceDana Faratian, Ashley Graham, Frances Rae, et al.
Discovery Medicine|October 1, 2009
How can systems pathology help us personalize cancer therapy?Dana Faratian, Simon P Langdon, David J Harrison
Pharmacogenomics|December 19, 2007
Dynamic computational modeling in the search for better breast cancer drug therapyDana Faratian, Stuart L Moodie, David J Harrison, et al.
Histopathology|February 12, 2009
Membranous and cytoplasmic staining of Ki67 is associated with HER2 and ER status in invasive breast carcinomaDana Faratian, Alison Munro, Christopher Twelves, et al.
Nature Reviews. Clinical Oncology|July 8, 2009
Systems pathology--taking molecular pathology into a new dimensionDana Faratian, Robert G Clyde, John W Crawford, et al.
Histopathology|February 25, 2009
Pleural Wegener's granulomatosis: a rare presentationDana Faratian, Bonnie Marr, Friederike Böllert, et al.
Expert Opinion on Biological Therapy|May 15, 2010
Pertuzumab for the treatment of ovarian cancerSimon P Langdon, Dana Faratian, Yoko Nagumo, et al.
Pageof 5

Showing results (1-10 of 47) with videos related to

Sort By:
Pageof 5
Breast Cancer Research : BCR|December 22, 2010
Systems pathologyDana Faratian
Current Drug Targets|September 15, 2012
Molecular pathology in therapeutics: where are we now, and where are we going?David J Harrison, Dana Faratian
Onkologie|November 6, 2009
The importance of growth factors and steroid hormones in ovarian cancerSimon P Langdon, Dana Faratian, David J Harrison
Histopathology|March 25, 2009
Rapid screening of tissue microarrays for Her-2 fluorescence in situ hybridization testing is an accurate, efficient and economic method of providing an entirely in situ hybridization-based Her-2 testing serviceDana Faratian, Ashley Graham, Frances Rae, et al.
Discovery Medicine|October 1, 2009
How can systems pathology help us personalize cancer therapy?Dana Faratian, Simon P Langdon, David J Harrison
Pharmacogenomics|December 19, 2007
Dynamic computational modeling in the search for better breast cancer drug therapyDana Faratian, Stuart L Moodie, David J Harrison, et al.
Histopathology|February 12, 2009
Membranous and cytoplasmic staining of Ki67 is associated with HER2 and ER status in invasive breast carcinomaDana Faratian, Alison Munro, Christopher Twelves, et al.
Nature Reviews. Clinical Oncology|July 8, 2009
Systems pathology--taking molecular pathology into a new dimensionDana Faratian, Robert G Clyde, John W Crawford, et al.
Histopathology|February 25, 2009
Pleural Wegener's granulomatosis: a rare presentationDana Faratian, Bonnie Marr, Friederike Böllert, et al.
Expert Opinion on Biological Therapy|May 15, 2010
Pertuzumab for the treatment of ovarian cancerSimon P Langdon, Dana Faratian, Yoko Nagumo, et al.
Pageof 5